Effect of amphotericin B lipid formulation on immune response in aspergillosis

被引:11
|
作者
Saxena, S
Bhatnagar, PK
Ghosh, PC
Sarma, PU
机构
[1] Ctr Biochem Technol, Delhi 7, India
[2] Univ Delhi, Dept Biochem, New Delhi 21, India
关键词
Aspergillus fumigatus; immuneregulation; amphotericin B; sterol vesicles; cytokines; lesions;
D O I
10.1016/S0378-5173(99)00200-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The immune response against Aspergillus fumigatus has been studied during infection and therapy in order to understand the mechanism of pathogenesis and the effect of treatment with amphotericin B. With this in view an animal model of aspergillosis was developed in Balb/c mice by intravenous injection of an optimized dose of 3.6 x 10(6) A. fumigatus spores. Infection due to Aspergillus was well established by histopathological examination and fungal load in the animal. Lesions and eosinophil infiltration was observed in the infected tissues which indicated the involvement of a Type I hypersensitivity response. Evaluation of serological parameters indicated high levels of interleukin-4 (IL-4) and A. fumigatus specific IgG antibodies. The reduction in fungal load and modulation of immune response in the infected mice was studied following treatment with amphotericin B/cholesterol hemisuccinate Vesicles (ABCV). The results clearly indicated significant reduction in the fungal load, disappearance of eosinophils and lesions with the appearance of macrophages and neutrophils in the infected lung tissue, a decrease in IL-4 (fourfold) and a concomitant increase of interferon-gamma (IFN-gamma; twofold) with an improvement in general condition of mice. In the non-treated mice, the rise of IL-4 level indicated the association of T(H)2 cell response with susceptibility to infection while the increase of IFN-gamma in the treated group suggested that T(H)1 cell response may be involved in resistance to Aspergillus infection. (C) 1999 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:19 / 30
页数:12
相关论文
共 50 条
  • [1] Progressive disseminated aspergillosis in a bone marrow transplant recipient: Response with a high-dose lipid formulation of amphotericin B
    Kontoyiannis, DP
    Andersson, BS
    Lewis, RE
    Raad, II
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) : E94 - E96
  • [2] Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis
    Kontoyiannis, DP
    Boktour, M
    Hanna, H
    Torres, HA
    Hachem, R
    Raad, II
    CANCER, 2005, 103 (11) : 2334 - 2337
  • [3] Does Combination of Lipid Formulation of Amphotericin B and Echinocandins Improve Outcome of Invasive Aspergillosis in Hematological Malignancy Patients?
    Mihu, Coralia N.
    Kassis, Christelle
    Ramos, Elizabeth R.
    Jiang, Ying
    Hachem, Ray Y.
    Raad, Issam I.
    CANCER, 2010, 116 (22) : 5290 - 5296
  • [4] Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B
    Amato, Valdir Sabbaga
    Tuon, Felipe Francisco
    Campos, Aleia
    Bacha, Helio Arthur
    Nicodemo, Antonio Carlos
    Neto, Vicente Amato
    Shikanai-Yasuda, Maria Aparecida
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (02) : 311 - 312
  • [5] Guidelines for the reconstitution of the correct amphotericin B lipid formulation
    Keady, Simon
    Panesar, Preet
    Damianos, Janet
    EJHP PRACTICE, 2010, 16 (03): : 78 - 80
  • [6] Role of the lipid formulation of amphotericin B in pediatric oncohematology
    Leverger, G
    PRESSE MEDICALE, 2000, 29 (22): : 1266 - 1267
  • [7] Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis
    Lestner, Jodi M.
    Howard, Susan J.
    Goodwin, Joanne
    Gregson, Lea
    Majithiya, Jayesh
    Walsh, Thomas J.
    Jensen, Gerard M.
    Hope, William W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (08) : 3432 - 3441
  • [8] Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients
    Chandrasekar, PH
    Ito, JI
    CLINICAL INFECTIOUS DISEASES, 2005, 40 : S392 - S400
  • [9] Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy
    Hachem, Ray Y.
    Boktour, Maha R.
    Hanna, Hend A.
    Husni, Rola N.
    Torres, Harrys A.
    Afif, Claude
    Kontoyiannis, Dimitrios P.
    Raad, Issam I.
    CANCER, 2008, 112 (06) : 1282 - 1287
  • [10] New lipid formulation of amphotericin B: spectral and microscopic analysis
    Larabi, M
    Gulik, A
    Dedieu, JP
    Legrand, P
    Barratt, G
    Cheron, M
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2004, 1664 (02): : 172 - 181